Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 23.8% during trading on Wednesday . The stock traded as high as C$0.13 and last traded at C$0.13. 356,000 shares were traded during trading, an increase of 1% from the average session volume of 351,835 shares. The stock had previously closed at C$0.11.
Hemostemix Stock Performance
The stock’s fifty day simple moving average is C$0.09 and its two-hundred day simple moving average is C$0.07. The stock has a market capitalization of C$12.63 million, a P/E ratio of -7.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What is the MACD Indicator and How to Use it in Your Trading
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Short Selling: How to Short a Stock
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Which Wall Street Analysts are the Most Accurate?
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
